Literature DB >> 17280799

Cornering HIV: taking advantage of interactions between selective pressures.

S Avila-Ríos1, G Reyes-Terán, E Espinosa.   

Abstract

Adaptive immune responses, cellular restrictive factors and antiretroviral drugs, target multiple regions in the Human Immunodeficiency Virus (HIV) proteome, imposing diverse pressures to viral adaptation. However, the virus is remarkably able to escape from these pressures as mutations are selected. In many cases these mutants have diminished viral fitness. We propose that the concerted action of strategically placed agents and pressures in a host can limit HIV variation capacity while inhibiting its replication. These mechanisms would corner HIV by selecting conflicting adaptive mutations, each having a disadvantage in face of another selective pressure. This would keep the virus unable to efficiently escape the suppressive effects of selective pressures. Cornering between antiretroviral drugs and cytotoxic T lymphocytes may explain recent observations, and can be predicted and used in viral control strategies. This idea can be extended to numerous other identified sites in the viral genome that confer selective pressures. We describe these other sites and how they could be induced to interact in prophylactic or therapeutic cornering strategies, as well as their experimental verifications. Cornering would control HIV infection better than current strategies, focused on few, albeit important, sites in the HIV genome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17280799     DOI: 10.1016/j.mehy.2006.12.012

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  4 in total

1.  Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.

Authors:  Ouzama Nicholson; Fay DiCandilo; James Kublin; Xiao Sun; Erin Quirk; Michelle Miller; Glenda Gray; Jean Pape; Michael N Robertson; Devan V Mehrotra; Steven Self; Katherine Turner; Jorge Sanchez; Punnee Pitisuttithum; Ann Duerr; Sheri Dubey; Lisa Kierstead; Danilo Casimiro; Scott M Hammer For The Merck V/Hiv Vaccine Trials Network Study Team
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-23       Impact factor: 2.205

2.  Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study.

Authors:  Santiago Avila-Rios; Christopher E Ormsby; Jonathan M Carlson; Humberto Valenzuela-Ponce; Juan Blanco-Heredia; Daniela Garrido-Rodriguez; Claudia Garcia-Morales; David Heckerman; Zabrina L Brumme; Simon Mallal; Mina John; Enrique Espinosa; Gustavo Reyes-Teran
Journal:  Retrovirology       Date:  2009-08-10       Impact factor: 4.602

Review 3.  Evolutionary dynamics of HIV at multiple spatial and temporal scales.

Authors:  Alison L Hill; Daniel I S Rosenbloom; Martin A Nowak
Journal:  J Mol Med (Berl)       Date:  2012-05-03       Impact factor: 4.599

4.  Identification of Immunogenic Cytotoxic T Lymphocyte Epitopes Containing Drug Resistance Mutations in Antiretroviral Treatment-Naïve HIV-Infected Individuals.

Authors:  Juan Blanco-Heredia; Aarón Lecanda; Humberto Valenzuela-Ponce; Christian Brander; Santiago Ávila-Ríos; Gustavo Reyes-Terán
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.